Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs (original) (raw)

Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial

Arthritis Care & Research, 2016

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies

Erika García, Karina Santana, Daniel Xavier Xibille Friedmann

Reumatología Clínica, 2017

The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

Andrzej Pilc

Clinical Rheumatology, 2013

Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies

Erika García, Karina Santana, Daniel Xavier Xibille Friedmann

Reumatología Clínica, 2017

Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies

International Journal of Rheumatic Diseases, 2016

Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Cristiano Moura

Arthritis research & therapy, 2018

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

New England Journal of Medicine, 2012

Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis

Nandini Kishore

Journal of Pharmacology and Experimental Therapeutics, 2013

Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study

2019

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Irmgadt Sariego

Lancet (London, England), 2017

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

Jamie Geier

Annals of the rheumatic diseases, 2015

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib

Kay Myint, Soe Moe

ISRN Rheumatology, 2013

Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial

Arthritis Care & Research, 2017

Tofacitinib with Methotrexate in Third-Line Treatment of Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3 Trial

Tofacitinib, an oral Janus kinase inhibitor, in patients from Colombia with rheumatoid arthritis: Pooled efficacy and safety analyses of data from phase III studies

Juan Jaller

Revista Colombiana de Reumatología, 2018

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis

Mark Genovese

Arthritis research & therapy, 2016

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses

Rheumatology and therapy, 2018

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

Jonathan French

Arthritis & Rheumatism, 2012

The 6-month drug survival rate in patients with rheumatoid arthritis treated with tofacitinib

Burak Öz

Annals of Medical Research, 2021

Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial

Arthritis care & research, 2015

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Jamie Geier

Annals of the rheumatic diseases, 2017

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis

RMD open, 2016

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

Mark Genovese

Annals of Internal Medicine, 2013

Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study

Yoshiya Tanaka

Rheumatology (Oxford, England), 2018

Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice

Francisco Blanco

Annals of the Rheumatic Diseases, 2012

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib

Maria Kózka

Therapeutics and clinical risk management, 2018

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

Rheumatology (Oxford, England), 2016

Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? -A Cohort Study in a Colombian Population

Fernando Rodriguez-Florido